Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small‐Cell Lung Cancer

Small cell lung cancer (SCLC) is a leading cause of cancer death worldwide, with few treatment options. Rovalpituzumab tesirine (Rova‐T) is an antibody‐drug conjugate that targets delta‐like 3 on SCLC cells to deliver a cytotoxic payload directly to tumor cells. In this study, the cardiac safety pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldman, Jonathan W., Barve, Minal, Patel, Jyoti D., Wozniak, Antoinette, Dowlati, Afshin, Starodub, Alexander, Owonikoko, Taofeek K., Edenfield, William, Laurie, Scott A., Da Costa, Daniel, Lally, Satwant, Koch, Martina, Kosloski, Matthew P., Hoffman, David, Dy, Grace K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993269/
https://www.ncbi.nlm.nih.gov/pubmed/33340277
http://dx.doi.org/10.1111/cts.12928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993269/
https://www.ncbi.nlm.nih.gov/pubmed/33340277
http://dx.doi.org/10.1111/cts.12928

Ejemplares similares